NCT01901692View on ClinicalTrials.gov

Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 29, 2013

Primary Completion Date

January 20, 2017

Study Completion Date

August 31, 2017

Conditions
Hepatocellular Carcinoma
Interventions
RADIATION

TACE+External beam RT

Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE

DRUG

Sorafenib

Sorafenib 800 mg/day orally

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER